BAVA Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.…
Industry Peers
BiotechnologyKey Statistics
About Bavarian Nordic (CPH: BAVA)
›
Bavarian Nordic (CPH: BAVA) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,923 employees.
The shares were at 248.20 DKK on 19 November 2026, up 30.7% over 52 weeks. Its 52-week range is 171.30 DKK to 257.00 DKK: the price is 3.4% below the high and 44.9% above the low.
At a market capitalisation of 18.52B DKK, it trades at 22.3 times trailing earnings and 20.4 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 33% for BAVA.
Bavarian Nordic reports return on equity of 10.7%, an operating margin of 19.7% and revenue up 0.6% year over year.
It holds more cash than debt, a net cash position of 2.86B DKK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 297.50 DKK is 19.9% above the current price.